Lepimectin Composition for Rosacea Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for rosacea, particularly in men, often come with unpleasant side effects and are not entirely effective, due to the multi-factorial nature of the condition and the limited understanding of its pathogenesis.
Innovation Solution
The use of a pharmaceutical composition containing at least 80% 6'-ethyl-lepimectin and less than 20% 6'-methyl-lepimectin, known as lepimectin, which belongs to the milbemycin class, for topical, parenteral, or oral administration to treat dermatological conditions such as rosacea, utilizing its endectocidal activity to target nerve transmission and reduce inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (metronidazole, azelaic acid, benzoyl peroxide, retinoic acid, or cyclins) are used to treat rosacea, then the condition can be managed, but unpleasant side effects such as irritation or intolerance occur
Solution Approach 1:
The patent changes the chemical parameter by introducing a new active ingredient (lepimectin, a milbemycin derivative) with different pharmacological properties than conventional treatments. This chemical substitution maintains therapeutic effectiveness while reducing harmful side effects through a different mechanism of action targeting nerve transmission in invertebrates rather than conventional anti-inflammatory or antibacterial pathways
Solution Approach 2:
The patent employs a novel therapeutic agent (lepimectin) that acts rapidly and effectively for the intended treatment purpose. While not literally disposable, the compound provides effective treatment with a favorable safety profile that doesn't require long-term cumulative use, allowing for targeted treatment cycles that minimize exposure and side effects
2Adaptability or versatility
If multiple therapies are used to address the multi-factorial nature of rosacea, then various aspects of the condition can be targeted, but the complexity of treatment increases and effectiveness remains uncertain
Solution Approach 1:
The patent applies universality by using lepimectin, a single compound with broad-spectrum activity against multiple factors involved in rosacea pathogenesis. The milbemycin derivative addresses inflammatory, vascular, and potential infectious components through its mechanism of potentiating glutamate-gated chloride channels, providing multi-functional treatment coverage without requiring multiple separate therapies
Solution Approach 2:
The patent merges multiple therapeutic functions into a single agent (lepimectin). Rather than combining multiple separate medications to address different aspects of rosacea, the invention consolidates anti-inflammatory, anti-vascular, and anti-parasitic activities into one compound, simplifying the treatment regimen while maintaining comprehensive coverage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively treats rosacea with reduced side effects, providing a more suitable option for patients by leveraging the compounds' ability to potentiate chloride ion permeability in membranes, leading to hyperpolarization and paralysis of affected tissues.
Implementation Method 1
They act on nerve transmission in invertebrates by potentiating the permeability of nematode and insect membranes to chloride ions via glutamate-chloride channels
Implementation Method 2
This causes hyperpolarization of the neuromuscular membrane and leads to flaccid paralysis and then death of the parasite
Data Source
AI summary
The present invention relates to the use of 6'-ethyl-lepimectine, 6'-methyl-lepimectine or derivatives thereof for producing a pharmaceutical composition for the treatment of dermatological affections in human beings, in particular rosacea.